These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

765 related items for PubMed ID: 16059623

  • 1. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR, Continuing Outcomes Relevant to Evista (CORE) Investigators.
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [Abstract] [Full Text] [Related]

  • 2. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB, Geusens P, Barton IP, Felsenberg D.
    J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
    Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA.
    J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
    [Abstract] [Full Text] [Related]

  • 4. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD.
    J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
    [Abstract] [Full Text] [Related]

  • 5. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [Abstract] [Full Text] [Related]

  • 6. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
    Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR, CORE Investigators.
    J Natl Cancer Inst; 2004 Dec 01; 96(23):1751-61. PubMed ID: 15572757
    [Abstract] [Full Text] [Related]

  • 7. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE, Bjarnason NH, Neven P, Plouffe L, Johnston CC, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.
    Menopause; 2003 Dec 01; 10(4):337-44. PubMed ID: 12851517
    [Abstract] [Full Text] [Related]

  • 8. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH.
    J Bone Miner Res; 2005 Sep 01; 20(9):1507-13. PubMed ID: 16059622
    [Abstract] [Full Text] [Related]

  • 9. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD.
    J Bone Miner Res; 2008 Apr 01; 23(4):525-35. PubMed ID: 18072873
    [Abstract] [Full Text] [Related]

  • 10. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ.
    Arthritis Rheum; 2008 Jun 01; 58(6):1687-95. PubMed ID: 18512789
    [Abstract] [Full Text] [Related]

  • 11. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
    Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ.
    J Bone Miner Res; 2004 Aug 01; 19(8):1270-5. PubMed ID: 15231013
    [Abstract] [Full Text] [Related]

  • 12. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
    Mok CC, Ying KY, To CH, Ho LY, Yu KL, Lee HK, Ma KM.
    Ann Rheum Dis; 2011 May 01; 70(5):778-84. PubMed ID: 21187295
    [Abstract] [Full Text] [Related]

  • 13. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr 01; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 14. Raloxifene: results from the MORE study.
    Agnusdei D, Iori N.
    J Musculoskelet Neuronal Interact; 2000 Dec 01; 1(2):127-32. PubMed ID: 15758505
    [Abstract] [Full Text] [Related]

  • 15. Safety assessment of raloxifene over eight years in a clinical trial setting.
    Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL.
    Curr Med Res Opin; 2005 Sep 01; 21(9):1441-52. PubMed ID: 16197663
    [Abstract] [Full Text] [Related]

  • 16. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
    Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L, Stock JL.
    Bone; 2007 Apr 01; 40(4):843-51. PubMed ID: 17182297
    [Abstract] [Full Text] [Related]

  • 17. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.
    Bone; 2006 Aug 01; 39(2):237-43. PubMed ID: 16563890
    [Abstract] [Full Text] [Related]

  • 18. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH.
    J Bone Miner Res; 2006 Nov 01; 21(11):1785-90. PubMed ID: 17002571
    [Abstract] [Full Text] [Related]

  • 19. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov 01; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.
    J Am Geriatr Soc; 2006 May 01; 54(5):782-9. PubMed ID: 16696744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.